DK2696888T3 - Sammensætninger og fremgangsmåder til forebyggelse eller behandling af pulmonal fibrose - Google Patents
Sammensætninger og fremgangsmåder til forebyggelse eller behandling af pulmonal fibrose Download PDFInfo
- Publication number
- DK2696888T3 DK2696888T3 DK12771584.5T DK12771584T DK2696888T3 DK 2696888 T3 DK2696888 T3 DK 2696888T3 DK 12771584 T DK12771584 T DK 12771584T DK 2696888 T3 DK2696888 T3 DK 2696888T3
- Authority
- DK
- Denmark
- Prior art keywords
- kinase
- pharmaceutical composition
- another embodiment
- therapeutic
- lung
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Claims (8)
1. Farmaceutisk sammensætning til anvendelse ved behandling af pulmonal fibrose i et individ, der er et resultat af administration af bleomycin, en allergisk reaktion, inhalation af miljøpartikler, rygning, en bakteriel infektion, en viral infektion, mekanisk beskadigelse på en lunge af individet, afvisning af en lungetransplantation, en autoimmun lidelse, en genetisk lidelse eller en kombination deraf, hvilken pulmonal fibrose er kendetegnet ved mindst en patologi udvalgt fra gruppen, der består af en afvigende afsætning af et ekstracellulært matrix-protein i et pulmonalt interstitium, en afvigende fremme af fibroblastproliferation i lungen, en afvigende induktion af myofibroblastdifferentiering i lungen og en afvigende fremme af fastgørelse af myofibroblaster til en ekstracellulær matrix, sammenlignet med et normalt sundt kontrol individ, hvilken farmaceutiske sammensætning omfatter (a) en terapeutisk mængde af et polypeptid af aminosyresekvensen YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) eller en funktionel ækvivalent deraf, som er valgt fra gruppen, der består af et polypeptid af aminosyresekvensen FAKLAARLYRKALARQLGVAA (SEQ ID NO: 3); et polypeptid af aminosyresekvensen KAFAKLAARLYRKALAR-QLGVAA (SEQ ID NO: 4); og et polypeptid af aminosyresekvens HRRIKAWLKKIKALARQLGVAA (SEQ ID NO: 7); og (b) en farmaceutisk acceptabel bærer, hvor den terapeutiske mængde er effektiv (1) til at inhibere kinaseaktivitet af en kinase, som er valgt fra gruppen af en mitogen-aktiveret proteinkinase-aktiveret proteinkinase 2 (MK2), en mitogen-aktiveret proteinkinase-aktiveret proteinkinase 3 (MK3), en calcium/calmodulin-afhængig proteinkinase I (CaMKI, serin/threonin-specifik proteinkinase) og en BDNF/NT-3 vækstfaktorreceptor (TrkB, ty-rosinkinase); og (2) til at reducere fibroblastproliferation og ekstracellulær matrixaflejring i individets væv.
2. Farmaceutisk sammensætning til anvendelsen ifølge krav 1, hvor (a) den pulmonale fibrose er yderligere kendetegnet ved en betændelse i lungevævet; eller (b) den afvigende fibroblastproliferation og ekstracellulære matrixaflejring i vævet er kendetegnet ved en afvigende aktivitet af mitogen-aktiveret proteinkina-se-aktiveret proteinkinase 2 (MK2) i vævet sammenlignet med aktiviteten af mi-togen-aktiveret proteinkinase-aktiveret proteinkinase 2 (MK2) i vævet af et normalt sundt kontrolindivid.
3. Farmaceutisk sammensætning til anvendelse ifølge krav 2, hvor inflammationen er medieret af mindst et cytokin, som er valgt fra gruppen, der består af tu-mor-nekrosefaktor-alfa (TNF- a), interleukin-6 (IL-6) og interleukin-1 β (IL-1 β).
4. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor (a) den farmaceutiske sammensætning formuleres til intratracheal administration, såsom ved pulmonal inhalation; parenteral administration; intravenøs administration; eller intraperitoneal administration; eller (b) den farmaceutiske sammensætning omfatter yderligere mindst et yderligere terapeutisk middel.
5. Farmaceutisk sammensætning til anvendelse ifølge krav 4, hvor det yderligere terapeutiske middel: (a) er et glucocorticoid, som er valgt fra gruppen, der består af predni-son, budesonid, mometasonfuroat, fluticasonpropionat, fluticasonfuroat og en kombination deraf, eller (b) er en bronchodilator, som er valgt fra gruppen, der består af en leu-kotrienmodifikator, en anticholinerg bronchodilator, en korttidsvirkende 32-agonist og en langtidsvirkende 32-agonist og en kombination deraf; eller (c) er valgt fra gruppen, der består af et oprenset type-V-kollagen, en IL-13-receptor-antagonist, en proteintyrosinkinase-inhibitor, en endothe- lial-receptor-antagonist, en dobbelt endothelin-receptor-antagonist, en prostacyclin-analog, et anti-CTGF-monoklonalt antistof, en endothelin-receptor-antagonist (A-selektiv), AB0024, et lysyloxidase-lignende 2 (LOXL2)-monoklonalt antistof, en c-Jun N-terminal kinase (JNK)-inhibitor, pirfenidon, IFN-Y1b, et pan-neutraliserende lgG4-humant antistof mod alle tre TGF-3-isoformer, en TGF-3-aktiveringsinhibitor, et rekombinant humant pentraxin-2-protein (rhPTX-2), et bispecifikt IL-4/IL-13-antistof, et humaniseret monoklonalt antistof der er rettet mod inte-grin ανβ6, N-acetylcystein, sildenafil, en tumor-nekrosefaktor (TNF)-antagonist (etanercept) og en kombination deraf; eller (d) er et analgetisk middel eller et anti-infektionsmiddel.
6. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor bæreren er valgt fra gruppen, der består af en styret frigivelsesbærer, en forsinket frigivelsesbærer, en bærer med vedvarende frigivelse og en bærer med langvarig frigivelse.
7. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den terapeutiske mængde af den farmaceutiske sammensætning administreres via en inhalationsindretning der er udvalgt blandt en forstøver, en doseret dosisinhalator (MDI), en tørpulverinhalator (DPI) eller en tø rpu Iverforstøver.
8. Farmaceutisk sammensætning til anvendelsen ifølge krav 7, hvor den farmaceutiske sammensætning er i form af et tørt pulver, der omfatter mikropartikler med massemedian-aerodynamisk diameter (MMAD) på 1 til 5 pm.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474370P | 2011-04-12 | 2011-04-12 | |
| PCT/US2012/033368 WO2012142320A2 (en) | 2011-04-12 | 2012-04-12 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2696888T3 true DK2696888T3 (da) | 2019-03-25 |
Family
ID=47006527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12771584.5T DK2696888T3 (da) | 2011-04-12 | 2012-04-12 | Sammensætninger og fremgangsmåder til forebyggelse eller behandling af pulmonal fibrose |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9642888B2 (da) |
| EP (1) | EP2696888B1 (da) |
| JP (1) | JP6031510B2 (da) |
| KR (1) | KR101862291B1 (da) |
| CN (3) | CN108014340A (da) |
| AU (1) | AU2012242768B2 (da) |
| BR (1) | BR112013026313A8 (da) |
| CA (2) | CA2832910C (da) |
| DK (1) | DK2696888T3 (da) |
| ES (1) | ES2711670T3 (da) |
| HK (1) | HK1255005A1 (da) |
| MX (1) | MX359516B (da) |
| RU (1) | RU2620066C2 (da) |
| SG (2) | SG10201604560TA (da) |
| WO (1) | WO2012142320A2 (da) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2594281T3 (es) | 2007-01-10 | 2016-12-19 | Purdue Research Foundation | Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos |
| WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
| AU2009324661A1 (en) * | 2008-12-10 | 2011-07-07 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US9890195B2 (en) * | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| EP2575855A4 (en) * | 2010-05-24 | 2014-03-12 | Moerae Matrix Inc | METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE |
| US9642888B2 (en) | 2011-04-12 | 2017-05-09 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| FR2976587B1 (fr) * | 2011-06-20 | 2015-04-03 | Basf Beauty Care Solutions F | Methode de dosage in vitro par technique immunologique |
| WO2013134636A1 (en) | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
| CA2884802A1 (en) * | 2012-10-31 | 2014-05-08 | Galecto Biotech Ab | Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| ES2864862T3 (es) | 2013-03-12 | 2021-10-14 | Celltaxis Llc | Métodos de inhibición de la leucotrieno A4 hidrolasa |
| KR20150127245A (ko) | 2013-03-14 | 2015-11-16 | 켈탁시스, 인코퍼레이티드 | 류코트라이엔 a4 가수분해효소의 저해제 |
| US10149823B2 (en) | 2013-04-30 | 2018-12-11 | Otitopic Inc. | Dry powder formulations and methods of use |
| MX2016011852A (es) * | 2014-03-14 | 2017-05-09 | Moerae Matrix Inc | Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). |
| US10336788B2 (en) * | 2014-04-17 | 2019-07-02 | Moerae Matrix, Inc. | Inhibition of cardiac fibrosis in myocardial infarction |
| AU2015350151A1 (en) * | 2014-11-17 | 2017-06-01 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| KR20170102900A (ko) | 2015-01-08 | 2017-09-12 | 모레 매트릭스 인코포레이티드 | Mk2 저해제 펩타이드의 제형 |
| CN107921082A (zh) | 2015-03-12 | 2018-04-17 | 莫伊莱麦屈克斯公司 | 含有mk2抑制剂肽的组合物用于治疗非小细胞肺癌的用途 |
| US10195147B1 (en) | 2017-09-22 | 2019-02-05 | Otitopic Inc. | Dry powder compositions with magnesium stearate |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| CN107987128B (zh) * | 2017-11-17 | 2019-06-11 | 广东医科大学 | 一种功能多肽及其在制备防治肺纤维化药物中的应用 |
| US20210212988A1 (en) * | 2018-05-17 | 2021-07-15 | Actuate Therapeutics Inc. | Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors |
| EP3801559A4 (en) | 2018-05-31 | 2022-03-02 | Celltaxis, LLC | METHOD FOR REDUCING LUNG EXACERBATIONS IN PATIENTS SUFFERING FROM RESPIRATORY DISEASE |
| CN110108883A (zh) * | 2018-10-27 | 2019-08-09 | 广州呼吸健康研究院 | 用于筛选与靶治疗ards患者的msc精准医学的标志物组合 |
| CN109406795A (zh) * | 2018-11-20 | 2019-03-01 | 昆明医科大学 | 一种轻型脑外伤的血清分子诊断标记物及应用 |
| WO2021040673A1 (en) * | 2019-08-26 | 2021-03-04 | Alain Martin | Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without copd |
| USD958124S1 (en) | 2019-12-16 | 2022-07-19 | Samsung Electronics Co., Ltd. | Television receiver |
| USD978094S1 (en) | 2019-12-27 | 2023-02-14 | Samsung Electronics Co., Ltd. | Television receiver |
| WO2021146662A1 (en) * | 2020-01-17 | 2021-07-22 | Muhammed Majeed | Therapeutic compositions and methods for pulmonary fibrosis |
| CN112386682B (zh) * | 2020-02-12 | 2022-12-06 | 王斌 | 纤连蛋白在制备治疗新型冠状病毒肺炎药物中的应用 |
| US20230127499A1 (en) * | 2020-03-30 | 2023-04-27 | Figene, Llc | Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus |
| US20230141224A1 (en) * | 2020-04-01 | 2023-05-11 | Figene, Llc | Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards) |
| JP2023522921A (ja) * | 2020-04-21 | 2023-06-01 | リモデレス シーヴイ リミテッド | 肺組織に対する急性損傷のための新規治療法 |
| AU2021390125A1 (en) * | 2020-12-03 | 2023-06-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-connective tissue growth factor antibody |
| USD989726S1 (en) | 2020-12-03 | 2023-06-20 | Samsung Electronics Co., Ltd. | Television receiver |
| USD989017S1 (en) | 2020-12-03 | 2023-06-13 | Samsung Electronics Co., Ltd. | Television receiver |
| WO2022147172A1 (en) * | 2020-12-30 | 2022-07-07 | Briotech, Inc. | Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions |
| WO2022204045A1 (en) * | 2021-03-22 | 2022-09-29 | Spiritus Therapeutics, Inc. | Diagnostic and therapeutic uses of purified potent exosomes containing disease-based and therapy based signature cargo |
| CN113440431A (zh) * | 2021-08-02 | 2021-09-28 | 山西锦波生物医药股份有限公司 | 重组ⅲ型人源化胶原蛋白在头皮护理中的用途及包含其的头皮护理产品 |
| WO2023178169A2 (en) * | 2022-03-15 | 2023-09-21 | Anemoi Biotech Holdings, Inc. | Compositions and methods for treating the pathophysiology of severe viral infection |
| CN116789751B (zh) * | 2023-08-22 | 2023-11-17 | 中国农业大学 | 预防和/或治疗纤维化疾病的多肽及其应用 |
| CN117577330B (zh) * | 2024-01-15 | 2024-04-02 | 北京大学 | 预测非酒精性脂肪性肝病肝纤维化程度的装置及存储介质 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| ES286422Y (es) | 1982-10-08 | 1986-09-16 | Glaxo Group Limited | Dispositivo para administrar medicamentos a pacientes |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| AU591152B2 (en) | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| WO1993022443A1 (en) | 1992-04-24 | 1993-11-11 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| EP0733059B1 (en) | 1993-12-09 | 2000-09-13 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| JP2002540850A (ja) | 1999-04-05 | 2002-12-03 | ファーマシューティカル ディスカバリー コーポレイション | 微粉形成のための方法 |
| DK1808438T3 (da) | 1999-06-29 | 2014-10-27 | Mannkind Corp | Rensning og stabilisering af peptid og proteiner i lægemidler |
| NZ536796A (en) * | 2002-04-25 | 2007-03-30 | Scripps Research Inst | Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant |
| US20040219142A1 (en) * | 2002-07-19 | 2004-11-04 | Abbott Laboratories S.A. | Treatment of skin and nail disorders using TNFalpha inhibitors |
| EP2260718B1 (en) * | 2003-11-25 | 2014-10-22 | Virginia Tech Intellectual Properties, Inc. | Composition for animal consumption for use in reducing MAP kinase activity |
| EP1753428A4 (en) * | 2004-05-14 | 2010-09-15 | Abbott Lab | INHIBITORS OF KINASES AS THERAPEUTIC AGENTS |
| EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
| WO2006023944A2 (en) | 2004-08-23 | 2006-03-02 | Mannkind Corporation | Pulmonary delivery of inhibitors of phosphodiesterase type 5 |
| DK2322180T3 (da) | 2004-08-23 | 2015-06-15 | Mannkind Corp | Diketopiperazinsalte til lægemiddel-afgivelse |
| CN101227918A (zh) * | 2005-04-29 | 2008-07-23 | 加州大学评议会 | 治疗以炎症反应为特征的病理的肽和肽模拟物 |
| KR101643478B1 (ko) | 2005-09-14 | 2016-07-27 | 맨카인드 코포레이션 | 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법 |
| MX360812B (es) | 2006-02-22 | 2018-11-16 | Mannkind Corp | Un método para mejorar las propiedades farmacéuticas de micropartículas que contienen dicetopiperazina y un agente activo. |
| MX2008012794A (es) * | 2006-04-03 | 2008-10-15 | Teva Pharma | Microparticulas de farmacos. |
| ES2594281T3 (es) | 2007-01-10 | 2016-12-19 | Purdue Research Foundation | Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos |
| WO2008098096A1 (en) | 2007-02-08 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Anti-cytokine heterocyclic compounds |
| US20080282320A1 (en) | 2007-05-11 | 2008-11-13 | Denovo Andrew | Security Compliance Methodology and Tool |
| WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
| WO2009085191A2 (en) | 2007-12-21 | 2009-07-09 | Cabot Corporation | Syntactic foam compositions, pipelines insulated with same, and method |
| DK2349310T3 (da) * | 2008-10-20 | 2014-08-11 | Moerae Matrix Inc | Polypeptid til behandling eller forebyggelse af adhæsioner |
| AU2009324661A1 (en) * | 2008-12-10 | 2011-07-07 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| EP2575855A4 (en) | 2010-05-24 | 2014-03-12 | Moerae Matrix Inc | METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE |
| US9642888B2 (en) | 2011-04-12 | 2017-05-09 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
-
2012
- 2012-04-12 US US13/445,759 patent/US9642888B2/en not_active Expired - Fee Related
- 2012-04-12 JP JP2014505291A patent/JP6031510B2/ja not_active Expired - Fee Related
- 2012-04-12 AU AU2012242768A patent/AU2012242768B2/en not_active Ceased
- 2012-04-12 BR BR112013026313A patent/BR112013026313A8/pt not_active Application Discontinuation
- 2012-04-12 ES ES12771584T patent/ES2711670T3/es active Active
- 2012-04-12 DK DK12771584.5T patent/DK2696888T3/da active
- 2012-04-12 SG SG10201604560TA patent/SG10201604560TA/en unknown
- 2012-04-12 CA CA2832910A patent/CA2832910C/en not_active Expired - Fee Related
- 2012-04-12 CN CN201711403446.9A patent/CN108014340A/zh active Pending
- 2012-04-12 CN CN201280027012.2A patent/CN104302310A/zh active Pending
- 2012-04-12 CN CN201910892185.4A patent/CN111110850A/zh active Pending
- 2012-04-12 MX MX2013011771A patent/MX359516B/es active IP Right Grant
- 2012-04-12 RU RU2013150249A patent/RU2620066C2/ru not_active IP Right Cessation
- 2012-04-12 EP EP12771584.5A patent/EP2696888B1/en not_active Not-in-force
- 2012-04-12 SG SG2013075031A patent/SG194135A1/en unknown
- 2012-04-12 CA CA3042808A patent/CA3042808A1/en not_active Abandoned
- 2012-04-12 KR KR1020137029996A patent/KR101862291B1/ko active IP Right Grant
- 2012-04-12 WO PCT/US2012/033368 patent/WO2012142320A2/en active Application Filing
-
2017
- 2017-04-04 US US15/478,950 patent/US20190022169A1/en not_active Abandoned
-
2018
- 2018-11-06 HK HK18114121.3A patent/HK1255005A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3042808A1 (en) | 2012-10-18 |
| CN104302310A (zh) | 2015-01-21 |
| BR112013026313A2 (pt) | 2016-12-27 |
| US20190022169A1 (en) | 2019-01-24 |
| AU2012242768A1 (en) | 2013-10-24 |
| MX2013011771A (es) | 2014-07-30 |
| KR20140063517A (ko) | 2014-05-27 |
| BR112013026313A8 (pt) | 2018-01-30 |
| RU2620066C2 (ru) | 2017-05-22 |
| EP2696888B1 (en) | 2018-12-05 |
| MX359516B (es) | 2018-10-01 |
| CN111110850A (zh) | 2020-05-08 |
| US20120263680A1 (en) | 2012-10-18 |
| AU2012242768B2 (en) | 2017-10-12 |
| CA2832910C (en) | 2019-07-02 |
| US9642888B2 (en) | 2017-05-09 |
| WO2012142320A2 (en) | 2012-10-18 |
| JP2014533235A (ja) | 2014-12-11 |
| ES2711670T3 (es) | 2019-05-06 |
| SG194135A1 (en) | 2013-11-29 |
| WO2012142320A8 (en) | 2014-02-20 |
| NZ616672A (en) | 2016-04-29 |
| JP6031510B2 (ja) | 2016-11-24 |
| RU2013150249A (ru) | 2015-05-20 |
| EP2696888A2 (en) | 2014-02-19 |
| EP2696888A4 (en) | 2016-04-20 |
| HK1255005A1 (zh) | 2019-08-02 |
| CN108014340A (zh) | 2018-05-11 |
| WO2012142320A3 (en) | 2015-06-11 |
| SG10201604560TA (en) | 2016-07-28 |
| CA2832910A1 (en) | 2012-10-18 |
| KR101862291B1 (ko) | 2018-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2696888T3 (da) | Sammensætninger og fremgangsmåder til forebyggelse eller behandling af pulmonal fibrose | |
| US10500249B2 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| US10562947B2 (en) | Compositions and methods for preventing or treating diseases, conditions or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| JP6655547B2 (ja) | 慢性肺移植片機能不全（ｃｌａｄ）および特発性肺線維症（ｉｐｆ）を予防または処置するための組成物および方法 | |
| NZ616672B2 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |